References
1. ”Inderal® (Propranolol) [Package Insert]. U.S. Food and Drug
Administration. Wyeth Pharmaceuticals, Inc. Available From:
Https://Www.Accessdata.Fda.Gov/Drugsatfda_Docs/Label/2011/016418s080,016762s017,017683s008lbl.Pdf.
Accessed August 19, 2020.”.
2. Groszmann, R.J.;Garcia-Tsao, G.;Bosch, J.;Grace, N.D.;Burroughs,
A.K.;Planas, R.;Escorsell, A.;Garcia-Pagan, J.C.;Patch, D.;Matloff,
D.S., et al. ”Beta-Blockers to Prevent Gastroesophageal Varices in
Patients with Cirrhosis.” N Engl J Med 353, no. 21 (2005):
2254-61.
3. Kroeger, R.J.;Groszmann, R.J. ”Increased Portal Venous Resistance
Hinders Portal Pressure Reduction During the Administration of
Beta-Adrenergic Blocking Agents in a Portal Hypertensive Model.”Hepatology 5, no. 1 (1985): 97-101.
4. Haq, I.;Tripathi, D. ”Recent Advances in the Management of Variceal
Bleeding.” Gastroenterol Rep (Oxf) 5, no. 2 (2017): 113-26.
5. Jalan, R.;Hayes, P.C. ”Uk Guidelines on the Management of Variceal
Haemorrhage in Cirrhotic Patients. British Society of Gastroenterology.”Gut 46 Suppl 3-4 (2000): III1-III15.
6. Nies, A.S.;Shand, D.G. ”Clinical Pharmacology of Propranolol.”Circulation 52, no. 1 (1975): 6-15.
7. Rowland, M.;Tozer, T.N. Clinical Pharmacokinetics Concepts and
Application. . 4th ed: Lippincott Williams&Wilkins, 4th edition, 2010.
8. Delco, F.;Tchambaz, L.;Schlienger, R.;Drewe, J.;Krahenbuhl, S. ”Dose
Adjustment in Patients with Liver Disease.” Drug Saf 28, no. 6
(2005): 529-45.
9. Tonami, N.;Nakajima, K.;Hisada, K.;Tanaka, N.;Kobayashi, K. ”A
Noninvasive Method for Evaluating Portal Circulation by Administration
of Ti-201 Per Rectum.” J Nucl Med 23, no. 11 (1982): 965-72.
10. D’Arienzo, A.;Celentano, L.;Scuotto, A.;Di Siervi, P.;Lombardi,
V.;Squame, G.;Mazzacca, G. ”Thallium-201 Per Rectum for the Diagnosis of
Cirrhosis in Patients with Asymptomatic Chronic Hepatitis.”Hepatology 8, no. 4 (1988): 785-7.
11. Lee, M.H.;Tae, H.J.;Jun, D.W.;Ryu, S.E.;Choi, Y.Y.;Kwak, M.J.;Kang,
J.S. ”201tl Heart-Liver Radioactivity Uptake Ratio and Prediction of
Decompensation in Patients with Cirrhosis.” Clin Nucl Med 38, no.
3 (2013): 169-74.
12. Watson, R.G.;Bastain, W.;Larkin, K.A.;Hayes, J.R.;McAinsh,
J.A.;Shanks, R.G. ”A Comparative Pharmacokinetic Study of Conventional
Propranolol and Long Acting Preparation of Propranolol in Patients with
Cirrhosis and Normal Controls.” Br J Clin Pharmacol 24, no. 4
(1987): 527-35.
13. Taegtmeyer, A.B.;Haschke, M.;Tchambaz, L.;Buylaert, M.;Tschopl,
M.;Beuers, U.;Drewe, J.;Krahenbuhl, S. ”A Study of the Relationship
between Serum Bile Acids and Propranolol Pharmacokinetics and
Pharmacodynamics in Patients with Liver Cirrhosis and in Healthy
Controls.” PLoS One 9, no. 6 (2014): e97885.
14. Xie, H.G.;Chen, X. ”Sex Differences in Pharmacokinetics of Oral
Propranolol in Healthy Chinese Volunteers.” Zhongguo Yao Li Xue
Bao 16, no. 5 (1995): 468-70.
15. Walle, T.;Walle, U.K.;Cowart, T.D.;Conradi, E.C. ”Pathway-Selective
Sex Differences in the Metabolic Clearance of Propranolol in Human
Subjects.” Clin Pharmacol Ther 46, no. 3 (1989): 257-63.
16. Walle, T.;Walle, K.;Mathur, R.S.;Palesch, Y.Y.;Conradi, E.C.
”Propranolol Metabolism in Normal Subjects: Association with Sex Steroid
Hormones.” Clin Pharmacol Ther 56, no. 2 (1994): 127-32.
Table 1. Demographic data of the subjects who completed study